AMGN vs DXCM
By Alex · Tickerpine
Amgen Inc. vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | AMGN | DXCM |
|---|---|---|
| Price | $416.18 | $90.80 |
| Market cap | $225.15B | $34.26B |
| P/E ratio | 25.7 | 35.9 |
| ROE | 91.47% | 38.49% |
| Profit margin | 22.95% | 20.12% |
| Revenue growth | 9.50% | 13.10% |
| Dividend yield | 2.43% | — |
| Beta | 0.41 | 1.41 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
AMGN vs DXCM in plain English
- AMGN is the bigger company — about 6.6× the market cap of DXCM.
- AMGN is cheaper on earnings (P/E 25.7 vs 35.9).
- AMGN earns a higher return on equity (91% vs 38%).
- DXCM is growing revenue faster (13% vs 10%).
- AMGN pays a dividend (2.43%) while the other effectively doesn't.
How would $1,000 have done in each?
AMGN return calculator
See what $1,000 in Amgen Inc. would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.